Bayer Aktiengesellschaft (BAYRY) has seen a series of highs and lows in the current financial market. In spite of several years of losses, the stock is projected to experience a
40% rebound. Yet the shares have been down 4.1% adding to investor concerns. There are implications drawn from Bayer's
observational study on ARDS and its strong cancer drug demand might provide a ray of light. However, the
forecast of a 2025 earnings fall has severely impacted the confidence leading to shares sinking to a 20-year low. Alongside this, the company suffered from a $2B penalty in the latest Roundup Case, further causing the stock to slump. Despite these challenges, promising signs have appeared, including Goldman Sachs upgrading Bayer's stock rating citing
positive catalysts and the
Q1's earnings exceeded estimates despite a hit in the Crop Science Unit sales. There are also concerns as shareholders call on the CEO to stem the tide of bad news and the share drop has attracted market regulator's scrutiny. Bayer is reportedly planning to settle Roundup lawsuits, which is positively affecting shares. The
end of the negative earnings revision cycle has prompted Goldman to raise Bayer to 'Buy'.
BAYER Stocks News Analytics from Wed, 25 Sep 2024 07:00:00 GMT to Fri, 04 Jul 2025 10:40:37 GMT -
Rating -2
- Innovation 3
- Information 5
- Rumor -6
